Cargando…

CRISPR/Cas9-Induced DNA Damage Enriches for Mutations in a p53-Linked Interactome: Implications for CRISPR-Based Therapies

Inactivating p53 mutations are the most abundant genetic alterations found in cancer. Here we show that CRISPR/Cas9-induced double-stranded DNA breaks enrich for cells deficient in p53 and in genes of a core CRISPR–p53 tumor suppressor interactome. Such enrichment could predispose to cancer developm...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiang, Long, Ingelshed, Katrine, Shen, Yunbing, Boddul, Sanjaykumar V., Iyer, Vaishnavi Srinivasan, Kasza, Zsolt, Sedimbi, Saikiran, Lane, David P., Wermeling, Fredrik
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9397613/
https://www.ncbi.nlm.nih.gov/pubmed/34750099
http://dx.doi.org/10.1158/0008-5472.CAN-21-1692
_version_ 1784772158046601216
author Jiang, Long
Ingelshed, Katrine
Shen, Yunbing
Boddul, Sanjaykumar V.
Iyer, Vaishnavi Srinivasan
Kasza, Zsolt
Sedimbi, Saikiran
Lane, David P.
Wermeling, Fredrik
author_facet Jiang, Long
Ingelshed, Katrine
Shen, Yunbing
Boddul, Sanjaykumar V.
Iyer, Vaishnavi Srinivasan
Kasza, Zsolt
Sedimbi, Saikiran
Lane, David P.
Wermeling, Fredrik
author_sort Jiang, Long
collection PubMed
description Inactivating p53 mutations are the most abundant genetic alterations found in cancer. Here we show that CRISPR/Cas9-induced double-stranded DNA breaks enrich for cells deficient in p53 and in genes of a core CRISPR–p53 tumor suppressor interactome. Such enrichment could predispose to cancer development and thus pose a challenge for clinical CRISPR use. Transient p53 inhibition could suppress the enrichment of cells with these mutations. The level of DNA damage response induced by an sgRNA influenced the enrichment of p53-deficient cells and could be a relevant parameter in sgRNA design to limit cellular enrichment. Furthermore, a dataset of >800 human cancer cell lines identified additional factors influencing the enrichment of p53-mutated cells, including strong baseline CDKN1A expression as a predictor for an active CRISPR–p53 axis. Taken together, these data provide details about p53 biology in the context of CRISPR-induced DNA damage and identify strategies to enable safer CRISPR use. SIGNIFICANCE: CRISPR-mediated DNA damage enriches for cells with escape mutations in a core CRISPR–p53 interactome, which can be suppressed by transient inhibition of p53.
format Online
Article
Text
id pubmed-9397613
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher American Association for Cancer Research
record_format MEDLINE/PubMed
spelling pubmed-93976132023-01-05 CRISPR/Cas9-Induced DNA Damage Enriches for Mutations in a p53-Linked Interactome: Implications for CRISPR-Based Therapies Jiang, Long Ingelshed, Katrine Shen, Yunbing Boddul, Sanjaykumar V. Iyer, Vaishnavi Srinivasan Kasza, Zsolt Sedimbi, Saikiran Lane, David P. Wermeling, Fredrik Cancer Res Genome and Epigenome Inactivating p53 mutations are the most abundant genetic alterations found in cancer. Here we show that CRISPR/Cas9-induced double-stranded DNA breaks enrich for cells deficient in p53 and in genes of a core CRISPR–p53 tumor suppressor interactome. Such enrichment could predispose to cancer development and thus pose a challenge for clinical CRISPR use. Transient p53 inhibition could suppress the enrichment of cells with these mutations. The level of DNA damage response induced by an sgRNA influenced the enrichment of p53-deficient cells and could be a relevant parameter in sgRNA design to limit cellular enrichment. Furthermore, a dataset of >800 human cancer cell lines identified additional factors influencing the enrichment of p53-mutated cells, including strong baseline CDKN1A expression as a predictor for an active CRISPR–p53 axis. Taken together, these data provide details about p53 biology in the context of CRISPR-induced DNA damage and identify strategies to enable safer CRISPR use. SIGNIFICANCE: CRISPR-mediated DNA damage enriches for cells with escape mutations in a core CRISPR–p53 interactome, which can be suppressed by transient inhibition of p53. American Association for Cancer Research 2022-01-01 2021-11-18 /pmc/articles/PMC9397613/ /pubmed/34750099 http://dx.doi.org/10.1158/0008-5472.CAN-21-1692 Text en ©2021 The Authors; Published by the American Association for Cancer Research https://creativecommons.org/licenses/by-nc-nd/4.0/This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) license.
spellingShingle Genome and Epigenome
Jiang, Long
Ingelshed, Katrine
Shen, Yunbing
Boddul, Sanjaykumar V.
Iyer, Vaishnavi Srinivasan
Kasza, Zsolt
Sedimbi, Saikiran
Lane, David P.
Wermeling, Fredrik
CRISPR/Cas9-Induced DNA Damage Enriches for Mutations in a p53-Linked Interactome: Implications for CRISPR-Based Therapies
title CRISPR/Cas9-Induced DNA Damage Enriches for Mutations in a p53-Linked Interactome: Implications for CRISPR-Based Therapies
title_full CRISPR/Cas9-Induced DNA Damage Enriches for Mutations in a p53-Linked Interactome: Implications for CRISPR-Based Therapies
title_fullStr CRISPR/Cas9-Induced DNA Damage Enriches for Mutations in a p53-Linked Interactome: Implications for CRISPR-Based Therapies
title_full_unstemmed CRISPR/Cas9-Induced DNA Damage Enriches for Mutations in a p53-Linked Interactome: Implications for CRISPR-Based Therapies
title_short CRISPR/Cas9-Induced DNA Damage Enriches for Mutations in a p53-Linked Interactome: Implications for CRISPR-Based Therapies
title_sort crispr/cas9-induced dna damage enriches for mutations in a p53-linked interactome: implications for crispr-based therapies
topic Genome and Epigenome
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9397613/
https://www.ncbi.nlm.nih.gov/pubmed/34750099
http://dx.doi.org/10.1158/0008-5472.CAN-21-1692
work_keys_str_mv AT jianglong crisprcas9induceddnadamageenrichesformutationsinap53linkedinteractomeimplicationsforcrisprbasedtherapies
AT ingelshedkatrine crisprcas9induceddnadamageenrichesformutationsinap53linkedinteractomeimplicationsforcrisprbasedtherapies
AT shenyunbing crisprcas9induceddnadamageenrichesformutationsinap53linkedinteractomeimplicationsforcrisprbasedtherapies
AT boddulsanjaykumarv crisprcas9induceddnadamageenrichesformutationsinap53linkedinteractomeimplicationsforcrisprbasedtherapies
AT iyervaishnavisrinivasan crisprcas9induceddnadamageenrichesformutationsinap53linkedinteractomeimplicationsforcrisprbasedtherapies
AT kaszazsolt crisprcas9induceddnadamageenrichesformutationsinap53linkedinteractomeimplicationsforcrisprbasedtherapies
AT sedimbisaikiran crisprcas9induceddnadamageenrichesformutationsinap53linkedinteractomeimplicationsforcrisprbasedtherapies
AT lanedavidp crisprcas9induceddnadamageenrichesformutationsinap53linkedinteractomeimplicationsforcrisprbasedtherapies
AT wermelingfredrik crisprcas9induceddnadamageenrichesformutationsinap53linkedinteractomeimplicationsforcrisprbasedtherapies